CN-680000-ME216-A2.pdf

AHCA CONTRACT NO. MED216

AMENDMENT NO. 2

AHCA Contract No. MED216, Amendment No. 2, Page 1 of 3 AHCA Form 2100-0003 (Rev. May 31, 2021)

THIS CONTRACT, entered into between the STATE OF FLORIDA, AGENCY FOR HEALTH CARE ADMINISTRATION, hereinafter referred to as the "Agency" and FLORIDA MEDICAL SCHOOLS QUALITY NETWORK, INC., hereinafter referred to as the "Vendor," is hereby amended as follows:

1. Standard Contract, Section II., THE AGENCY HEREBY AGREES, Sub-Section A., Contract Amount, the first sentence is hereby amended to now read as follows:

To pay for contracted services according to the conditions of Attachment I., Scope of Services, in an amount not to exceed $545,002.00, (an increase of $197,037.00), subject to the availability of funds.

2. Standard Contract, Section III., THE VENDOR AND AGENCY HEREBY MUTUALLY AGREE, Sub-Section B., Contract Managers, Item 1., is hereby amended to now read as follows:

1. The Agency’s Contract Manager’s contact information is as follows:

LaKacea Smith Agency for Health Care Administration 2727 Mahan Drive, MS# 38 Tallahassee, FL 32308

(850) 412-4214 LaKacea.Smith@ahca.myflorida.com

3. Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-

Section B., Services Provided by the Vendor, Item 1., Projects to be Completed by the Vendor, is hereby amended to now include Sub-Item b., Project 2: Sickle Cell Disease Study.

b. Project 2: Sickle Cell Disease Study

The purpose of this project is to conduct a study and produce a report on sickle cell disease as described in the 2022 General Appropriations Act, Specific Appropriation 189. The Agency shall submit the report to the Governor, the President of the Senate, the Speaker of the House of Representatives, Florida Department of Health Office of Minority Health and Health Equity and Rare Disease Advisory Council by February 1, 2023. The Vendor shall conduct the following activities, at a minimum, in meeting the requirements of this Contract:

1) Identify the total population of Medicaid enrollees with a diagnosis of sickle cell disease.

2) Identify the total population of Medicaid enrollees who have experienced two (2) or more emergency room visits or two (2) or more inpatient admissions in the most recent twelve (12) month period in which complete data is available as approved by the Agency.

DocuSign Envelope ID: 4C1083B4-8CEC-4337-9057-AC1EAAB577F2DocuSign Envelope ID: 65994A3F-9059-4991-88CC-0B24C7898505 mailto:LaKacea.Smith@ahca.myflorida.com mailto:LaKacea.Smith@ahca.myflorida.com

AHCA Contract No. MED216, Amendment No. 2, Page 2 of 3 AHCA Form 2100-0003 (Rev. May 31, 2021)

3) For both populations, provide the following detailed information:

i. Age and population demographics;

ii. Health care utilization patterns

iii. Expenditures for all pharmaceutical and medical services provided.

iv. Number of clinical treatment programs available that are contracted with managed care plans for the care of Florida Medicaid enrollees that are specifically designed or certified to provide health care coordination and health care access for individuals with SCD.

4) Consult with a dedicated sickle cell disease medical treatment and research center which maintains a sickle cell patient database and tracks sickle cell disease outcome measures.

5) Identify enrollees within the general sickle cell patient population who have experienced two or more emergency room visits or two (2) or more hospital inpatient admissions in twelve (12) month period. For both of those populations, the Vendor shall provide detailed information including:

• Age and population demographics.

• Health care utilization patterns.

• Expenditures for all pharmaceutical and medical services provided.

• Number of clinical treatment programs available that are contracted with managed care plans for the care of Medicaid enrollees that are specifically designed or certified to provide health care coordination and health care access for individuals with sickle cell disease.

6) Summarize evidence and best practice for sickle cell disease screening, diagnosis, treatment, and transition from the pediatric care setting to adult care setting.

4. Attachment I, Scope of Services, Exhibit A, Deliverables and Financial Consequences, is hereby amended to include Contract Year 2 (State Fiscal Year 2022 – 2023) deliverables as outlined in Exhibit A, Deliverables and Financial Consequences, attached hereto this Amendment, and made a part of this Contract.

All provisions not in conflict with this Amendment are still in effect and are to be performed at the level specified in this Contract.

This Amendment and all its attachments are hereby made a part of this Contract.

This Amendment cannot be executed unless all previous Amendments to this Contract have been fully executed.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: 4C1083B4-8CEC-4337-9057-AC1EAAB577F2DocuSign Envelope ID: 65994A3F-9059-4991-88CC-0B24C7898505

AHCA Contract No. MED216, Amendment No. 2, Page 3 of 3 AHCA Form 2100-0003 (Rev. May 31, 2021)

IN WITNESS WHEREOF, the Parties hereto have caused this four (4) page Amendment to be executed by their officials thereunto duly authorized. This Amendment is not valid until signed and dated by both Parties.

FLORIDA MEDICAL SCHOOLS QUALITY

NETWORK, INC.

STATE OF FLORIDA, AGENCY FOR

HEALTH CARE ADMINISTRATION

SIGNED

BY:

SIGNED

BY:

NAME: NAME:

TITLE: TITLE:

DATE: DATE:

List of Attachments included as part of this Amendment:

Specify Type Number Description

Attachment I Exhibit A Deliverables and Financial

Consequences (1 page)

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: 4C1083B4-8CEC-4337-9057-AC1EAAB577F2

SVP USF Health, Dean, Morsani College of Medicine

8/23/2022

Dr. Charles Lockwood

DocuSign Envelope ID: 65994A3F-9059-4991-88CC-0B24C7898505

Deputy Secretary of Medicaid

Tom Wallace

8/25/2022

ATTACHMENT I

EXHIBIT A

DELIVERABLES AND FINANCIAL CONSEQUENCES

AHCA Contract No. MED216, Attachment I, Exhibit A, Page 1 of 1 AHCA Form 2100-0003 (Rev. May 31, 2021)

6.

DELIVERABLE 6

Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report that in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B.

Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

November 1, 2022, or as otherwise approved in writing by the Agency.

AMOUNT

$118,222.20

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 1 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

7.

DELIVERABLE 7

Final Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

December 1, 2022, or as otherwise approved in writing by the Agency.

AMOUNT

$78,814.80

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 2 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

DocuSign Envelope ID: 4C1083B4-8CEC-4337-9057-AC1EAAB577F2DocuSign Envelope ID: 65994A3F-9059-4991-88CC-0B24C7898505